… management, reducing treatment burden and improving adherence. Cabotegravir plus rilpivirine (CAB/RPV LA) is the first complete long-acting…
All extracted drugs
Showing 1,201–1,260 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
Articles mentioning drugs
10,506 articles · page 236 of 876…Most patients were women with CM and prior mAb–antiCGRP failure.Atogepant led to a significant but modest MDM/TDM reduction, consistent w…
…ntified patients with prescriptions of piperacillin/tazobactam, cefepime, and carbapenems (meropenem, ertapenem, and imipenem/cilastatin…
…tectable VL and CD4+ >500/mm3 (p=0.32).Conclusion and Relevance Dolutegravir/lamivudine showed high effectiveness in patients with adherence rates abov…
…ed (75.96%) or familial hypercholesterolaemia were treated with inclisiran. The median baseline values of lipid parameters were: LDL 108.7…
…logical failure.Conclusion and Relevance Long-acting injectable CAB/RPV was effective and well-tolerated. Virological suppression at we…
…ore W12. Three patients combined atogepant with botulinum toxin.Atogepant was effective in 30% (n=9), 20% (n=6) showed partial improvemen…
…s To describe the experience with pharmacokinetic monitoring of posaconazole suspension in immunocompromised paediatric patients, and to eva…
…tive trend toward more appropriate and economically sustainable IVIg use in comparison with 2014. The formal inclusion of CIDP and M…
…RP antibodies. Treatment: 56 (82.6%) atogepant and nine (13.8%) rimegepant.Response rate: 18 (28.1%) had CR, six (9.4%) presented PR, 28 (…
…vance Despite the limited sample size, the results suggest that abemaciclib’s effectiveness seems consistent with MONARCH-3 results:Median …
…ts 1. National Institute for Health and Care Excellence (NICE). Sodium zirconium cyclosilicate for treating hyperkalaemia. NICE Technology Appraisal Guidance.…